This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYC
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
by Zacks Equity Research
Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.
Summit Therapeutics PLC (SMMT) Moves 17.4% Higher: Will This Strength Last?
by Zacks Equity Research
Summit Therapeutics PLC (SMMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Summit Therapeutics (SMMT) Surges: Stock Moves 7.2% Higher
by Zacks Equity Research
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
New Strong Sell Stocks for October 30th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.75, marking a +1.08% move from the previous day.
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SMMT) Outperforming Other Medical Stocks This Year?
Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Summit Therapeutics PLC (SMMT) closed at $4.20 in the latest trading session, marking a +1.94% move from the prior day.
Summit Therapeutics PLC (SMMT) Stock Moves -0.43%: What You Should Know
by Zacks Equity Research
In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.48, marking a -0.43% move from the previous day.
Will Ventilator Sales Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) might have registered lower demand for its emergency procedures in Q4 with patients trying to avoid any non-COVID-19 emergency treatment.
CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.
Is Summit Therapeutics (SMMT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (SMMT) Outperforming Other Medical Stocks This Year?
Summit Therapeutics PLC (SMMT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.11, moving +0.33% from the previous trading session.
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SMMT) Outperforming Other Medical Stocks This Year?
Summit Therapeutics PLC (SMMT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.68, moving +0.55% from the previous trading session.
Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Here's Why Momentum Investors Will Love Summit Therapeutics PLC (SMMT)
by Zacks Equity Research
Does Summit Therapeutics PLC (SMMT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SMMT) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: DHT, Summit Therapeutics, Sharps Compliance, Frontline and Kala Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DHT, Summit Therapeutics, Sharps Compliance, Frontline and Kala Pharmaceuticals
5 Stocks Up on Signs of Slowdown in Coronavirus Cases
by Zacks Equity Research
Coronavirus shows signs of slowdown in the United States and some other countries. While investors look for positive developments in the stock market, here are five must-buy stocks poised to grow.
Top Ranked Momentum Stocks to Buy for April 7th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 7th
Top Ranked Momentum Stocks to Buy for March 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 26th
Top Ranked Momentum Stocks to Buy for March 25th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 25th
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SMMT) Outperforming Other Medical Stocks This Year?